Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
08 Oct 2021
Historique:
entrez: 6 10 2021
pubmed: 7 10 2021
medline: 7 10 2021
Statut: ppublish

Résumé

Regional delivery of chimeric antigen receptor (CAR) T cells in glioblastoma represents a rational therapeutic approach as an alternative to intravenous administration to avoid the blood-brain barrier impediment. Here, we developed a fibrin gel that accommodates CAR-T cell loading and promotes their gradual release. Using a model of subtotal glioblastoma resection, we demonstrated that the fibrin-based gel delivery of CAR-T cells within the surgical cavity enables superior antitumor activity compared to CAR-T cells directly inoculated into the tumor resection cavity.

Identifiants

pubmed: 34613775
doi: 10.1126/sciadv.abg5841
pmc: PMC8494441
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabg5841

Subventions

Organisme : NCI NIH HHS
ID : T32 CA196589
Pays : United States

Références

Nat Cancer. 2020 Oct;1(10):990-997
pubmed: 33898999
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Am J Surg. 2001 Aug;182(2 Suppl):36S-39S
pubmed: 11566475
J Mater Chem B. 2015 Oct 28;3(40):7986-7992
pubmed: 26509037
J Natl Cancer Inst. 2016 Jun 22;108(11):
pubmed: 27335052
J Immunother. 2019 May;42(4):126-135
pubmed: 30882547
Cancer Cell. 2020 Feb 10;37(2):216-225.e6
pubmed: 32004441
J Biomed Mater Res. 2002 Sep 5;61(3):474-81
pubmed: 12115473
Nano Lett. 2019 Mar 13;19(3):1701-1705
pubmed: 30773888
Clin Med Oncol. 2008;2:421-2
pubmed: 21892310
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
EBioMedicine. 2019 Sep;47:33-43
pubmed: 31466914
Clin Cancer Res. 2020 Jun 1;26(11):2444-2451
pubmed: 32015021
J R Soc Interface. 2009 Jan 6;6(30):1-10
pubmed: 18801715
J Clin Oncol. 2009 Oct 1;27(28):4733-40
pubmed: 19720927
JAMA Oncol. 2017 Aug 1;3(8):1094-1101
pubmed: 28426845
J Clin Invest. 2016 Jul 1;126(7):2588-96
pubmed: 27270177
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
J Vis Exp. 2018 Jul 16;(137):
pubmed: 30059037
Pharmaceutics. 2019 Oct 28;11(11):
pubmed: 31661853
Adv Drug Deliv Rev. 2018 Apr;129:134-147
pubmed: 29247766
Blood. 2006 Dec 1;108(12):3890-7
pubmed: 16926291
Blood. 2014 Jun 12;123(24):3750-9
pubmed: 24782509
Sci Transl Med. 2018 Feb 28;10(430):
pubmed: 29491184
Atherosclerosis. 2001 Oct;158(2):455-63
pubmed: 11583726
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Cancer Cell. 2019 Feb 11;35(2):221-237.e8
pubmed: 30753824
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573

Auteurs

Edikan A Ogunnaike (EA)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina at Chapel Hill, Raleigh, NC 27695, USA.
Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.

Alain Valdivia (A)

Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Mostafa Yazdimamaghani (M)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.

Ernesto Leon (E)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.

Seema Nandi (S)

Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina at Chapel Hill, Raleigh, NC 27695, USA.

Hannah Hudson (H)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.

Hongwei Du (H)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.

Simon Khagi (S)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Department of Medicine, Division of Medical Oncology, University of North Carolina, Chapel Hill, NC 27599, USA.

Zhen Gu (Z)

Department of Bioengineering, University of California, Los Angeles, CA 90095, USA.
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.

Barbara Savoldo (B)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Department of Pediatrics, University of North Carolina, Chapel Hill, NC 27514, USA.

Frances S Ligler (FS)

Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina at Chapel Hill, Raleigh, NC 27695, USA.
Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.

Shawn Hingtgen (S)

Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Gianpietro Dotti (G)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA.

Classifications MeSH